Immunocore Holdings plc (IMCR)
| Market Cap | 1.49B -16.3% |
| Revenue (ttm) | 429.30M +13.1% |
| Net Income | -32.12M |
| EPS | -0.63 |
| Shares Out | 51.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 181,450 |
| Open | 30.04 |
| Previous Close | 29.94 |
| Day's Range | 28.77 - 30.48 |
| 52-Week Range | 27.50 - 40.72 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 59.30 (+105.33%) |
| Earnings Date | Nov 6, 2026 |
About IMCR
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase ... [Read more]
Financial Performance
In 2025, Immunocore Holdings's revenue was $400.02 million, an increase of 28.95% compared to the previous year's $310.20 million. Losses were -$35.51 million, -30.48% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price target is $59.3, which is an increase of 105.33% from the latest price.
News
Immunocore price target lowered to $42 from $43 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Immunocore (IMCR) to $42 from $43 and keeps an Equal Weight rating on the shares. The firm adjusted estimates…
Immunocore price target lowered to $80 from $100 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Immunocore (IMCR) to $80 from $100 and keeps a Buy rating on the shares following the Q3 report. The firm cites later…
Immunocore to present at upcoming investor conferences
(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering...
Immunocore presents Phase 1/2 trial cohort data of brenetafusp plus KIMMTRAK
Immunocore (IMCR) Holdings presented data from its Phase 1/2 trial evaluating brenetafusp alone and in combination with KIMMTRAK in HLA-A*02:01-positive patients with metastatic uveal melanoma, in a p...
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remaine...
Immunocore reports third quarter financial results and provides a business update
KIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date
Immunocore Holdings Quarterly report: Q3 2026
Immunocore Holdings has published its Q3 2026 quarterly earnings report on November 6, 2026.
Immunocore Holdings Earnings release: Q3 2026
Immunocore Holdings released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
Immunocore Holdings Slides: Corporate presentation
Immunocore Holdings has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2026.
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK ® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore price target lowered to $33 from $35 at Mizuho
Mizuho lowered the firm’s price target on Immunocore (IMCR) to $33 from $35 and keeps a Neutral rating on the shares.
Immunocore doses first patient in IMC-S118AI trial
Immunocore (IMCR) announced that the first patient with type 1 diabetes, or T1D, has been dosed in the Phase 1 trial of IMC-S118AI. The Phase 1 dose escalation trial will…
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safet...
Immunocore Holdings Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-origin innovation is intensifying competition, shifting focus to complex, hard-to-copy targets. AI is streamlining R&D, while KIMMTRAK maintains strong market penetration and is poised for expansion pending positive trial results. The pipeline spans oncology, autoimmune, and infectious diseases, with disciplined capital allocation and potential partnerships supporting future growth.
Immunocore achieves target patient enrollment in TEBE-AM clinical trial
Immunocore (IMCR) announced the achievement of target patient enrollment in the TEBE-AM clinical trial. With target enrollment now achieved, patients enrolled in the trial will continue to be followed...
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as ea...
Immunocore Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A commercial-stage biotech highlighted strong KIMMTRAK sales, robust cash reserves, and a pipeline with three phase III trials nearing key data readouts. Expansion into new indications and ongoing innovation in TCR therapies position the company for multiple value-creating milestones in the next two to three years.
Immunocore reinstated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye reinstated coverage of Immunocore (IMCR) with an Overweight rating and $50 price target The firm thinks Kimmtrak offers a “solid foundation” that is still growing in…
Immunocore price target raised to $43 from $40 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Immunocore (IMCR) to $43 from $40 and keeps an Equal Weight rating on the shares.
Immunocore Holdings Earnings Call Transcript: Q2 2026
Strong H1 2026 revenue growth was driven by KIMMTRAK's commercial momentum and high market penetration, with five-year survival data reinforcing its clinical value. Pipeline progress continues across melanoma, ovarian, lung, HIV, and autoimmune diseases, supported by a robust balance sheet.
Immunocore Holdings Earnings release: Q2 2026
Immunocore Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Immunocore Holdings Quarterly report: Q2 2026
Immunocore Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Immunocore Holdings Slides: Q2 2026
Immunocore Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Immunocore reports second quarter financial results and provides a business update
Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in ...
Immunocore Holdings Slides: Corporate presentation
Immunocore Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.